- Abstract
- Keywords
- Introduction
- Chemistry of BD
- Antineoplastic effects of BD in human malignancies
- Anti-metastatic effects of BD
- Potential anti-inflammatory effects of BD
- Pharmacokinetics, toxicity and metabolism
- Clinical application of BD
- Conclusion and future directions
- Abbreviations
- Declarations
- References
-
Citing Article List
The journal uses Crossref Cited-by service counts times cited of published articles. Cited-by allows Crossref members to find out who is citing their content. This is the Citing Article List of “Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?”.No. Publication Date Citing Article 1 2023 Yang Xing, Feroza Yasinjan, Yajie Du, Huayue Geng, Ying Zhang, Minghua He, Rui Guo, Lei Yang, Jiayue Cui, Dongmei Mu, Ziling Liu, Hong Wang. Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials, Frontiers in Immunology. 2023; 14: 1094437. https://doi.org/10.3389/fimmu.2023.1094437 2 2023 Chukwunonso K. Nwabufo, Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations, Cancer Chemotherapy and Pharmacology. 2023; https://doi.org/10.1007/s00280-023-04575-y 3 2023 Rebecca L. Porter, Ursula A. Matulonis. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer, Expert Review of Anticancer Therapy. 2023; 23: 783. https://doi.org/10.1080/14737140.2023.2236793 -
